CN111269280B - Compound, corresponding internal standard and kit for detecting enzyme related to lysosomal storage disease - Google Patents
Compound, corresponding internal standard and kit for detecting enzyme related to lysosomal storage disease Download PDFInfo
- Publication number
- CN111269280B CN111269280B CN202010232077.7A CN202010232077A CN111269280B CN 111269280 B CN111269280 B CN 111269280B CN 202010232077 A CN202010232077 A CN 202010232077A CN 111269280 B CN111269280 B CN 111269280B
- Authority
- CN
- China
- Prior art keywords
- compound
- lysosomal storage
- enzyme
- internal standard
- detecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a compound, a corresponding internal standard and a kit for detecting enzymes related to lysosomal storage diseases. The compound has a structure shown as the following formula I:
the lysosomal storage disease-associated enzyme comprises one or more of acid β -glucocerebrosidase, β -galactocerebroside, α -galactosidase, and acid α -glucosidase. The compound for detecting the enzyme related to the lysosomal storage disease, provided by the invention, has the structure that the part for connecting the glucoside and the ammonia alcohol contains the benzene ring and the benzene ring is connected with the end part of the ammonia alcohol through an ester bond, so that the contact flexibility of the substrate and the related enzyme is improved, and the combination efficiency of the enzyme and the substrate can be improved. In addition, the invention preferably combines R1 and R2 to improve the specificity of detection and increase the detection sensitivity.
Description
Technical Field
The invention relates to the field of enzyme activity detection, in particular to a compound, a corresponding internal standard and a kit for detecting enzymes related to lysosomal storage disease.
Background
Lysosomal Storage Disorders (LSDs) are a group of inherited metabolic diseases, which are caused by defects in lysosomes due to gene mutations associated with acid hydrolases, resulting in the failure of the normal degradation of the corresponding biological macromolecules in the body to store in the lysosomes, causing dysfunction of tissues and organs. Lysosomal storage disorders can cause disease in a variety of systems, but can also be limited to the nervous system and can occur from birth to adulthood. The clinical symptoms are different, and the disease condition becomes worse progressively. Most lysosomal storage diseases are inherited in an autosomal recessive manner, with each disease having a low incidence rate but being one of the common human genetic diseases as a group of diseases. Although the symptoms of over 50 currently identified LSDs vary greatly, they share a common point-all caused by lysosomal lesions. Among them, the incidence of Fabry disease (Fabry) is 1/110000-1/40000, which results in the inability of the body to break down specific lipids called globotriaylsaccharide (globotriaylceramide) due to the absence of α -galactosidase; gaucher disease (Gaucher) is a lysosomal storage disease caused by an inability to break down glucocerebrosidase, which is an inability of patients to synthesize glucocerebrosidase, resulting in accumulation of these lipids in cells of the liver, spleen and bone marrow; pompe disease (Pompe) is a lysosomal storage disease caused by glycogen accumulation in various tissues and organs within the body due to a deficiency in acid alpha-glucosidase. Krabbe's disease (Krabbe) is developed by the deposition of many galactocerebrosides in the white matter due to a deficiency in β -galactocerebroside esterase in vivo. Niemanpex A/B, mucopolysaccharidosis type I (MPS-I) these diseases are mostly pediatric diseases. In most patients, the patient is normal at birth and begins to undergo neurological deterioration progressively some time later. In some patients, the disease manifests in adulthood, and the clinical phenotype depends on the type and severity of the biochemical defect.
The LSDs screening method mainly comprises the following steps: tandem mass spectrometry, fluorescence and multiple immunoassays (immunocapture method for measuring abundance of lysosomal enzyme), and detection of biomarkers. Fluorescence methods cannot simultaneously measure multiple enzyme activities due to non-specificity and are prone to higher false positives or false negatives, such as: the fluorogenic substrate of Niemann-Pick-A/B disease can cause serious false negative problems; the multi-immunoassay method and the biomarker detection method are difficult to popularize because of not being commercialized; the tandem mass spectrometry technology has high sensitivity and good accuracy, and can screen various diseases simultaneously in one experiment, thereby being more suitable for the auxiliary diagnosis of LSDs. In summary, the MS/MS method is suitable for screening newborn infants with Gaucher disease (Gaucher), Niemann pick disease (A/B), Krabbe disease (Krabbe), mucopolysaccharidosis type I (MPS-I), Fabry disease (Fabry) and Pompe disease, and can also be used for monitoring enzyme activity of relevant LSDs patients after treatment. However, the use of current enzyme substrates also has the disadvantages of insufficient stability, specificity and poor reactivity.
Therefore, in the current scientific research and practice, new substrates need to be designed to improve the stability, specificity and reaction rate of the substrates and improve the detection efficiency, reproducibility and accuracy.
Disclosure of Invention
In view of the deficiencies of the prior art LSDs tandem mass spectrometry, it is an object of the present invention to provide a compound for detecting an enzyme associated with a lysosomal storage disease as a substrate for binding to the associated enzyme.
The second object of the present invention is to provide an internal standard compound corresponding to the above compound.
It is a further object of the present invention to provide a kit for detecting an enzyme associated with a lysosomal storage disease.
A compound for detecting an enzyme associated with lysosomal storage disease, having the structure of formula i:
wherein G is a hexose linked by a glycosidic bond;
r1 is C1-C10Alkyl or C2-C20An alkenyl group;
r2 is C1-C20Alkyl, C having a substituent of N, O or S1-C20Alkyl radical, C3-C20Alkenyl or C having a substituent of N, O or S3-C20An alkenyl group;
r3 and R4 are each independently C1-C3Alkyl or H.
As for the compound for detecting the enzyme related to the lysosomal storage disease, the part for connecting the glucoside and the ammonia alcohol contains a benzene ring, and the benzene ring is connected with the end part of the ammonia alcohol through an ester bond, and related experiments prove that the structure can enhance the specificity of the substrate and the related enzyme and can improve the reaction efficiency of the enzyme and the substrate.
Specificity for a substrate (i.e., a compound of the invention) for a particular lysosomal enzyme can be provided by: the first moiety is provided by a sugar moiety G, for example G is β -glucose or β -galactose, and the substrate will be specific for a glycosidic bond capable of hydrolyzing such sugar; exemplary sugar moieties G can be alpha-D-glucose for detecting pompe disease; beta-D-glucose for the detection of gaucher disease; alpha-D-galactose for detecting Fabry's disease; and beta-D-galactose for detecting Krabbe's disease. A second part, where the specificity of the substrate is controlled by the coordination of R1 and R2, such as the variation of carbon length and degree of saturation within the R1 aliphatic amide group simultaneously coordinating the carbon chain length and degree of saturation of R2 to increase the specificity of the substrate for the enzyme; illustratively, R1 is a 6-8 carbon alkyl group and R2 is a 13 carbon saturated alkyl group with very desirable specificity for enzymes that function to hydrolyze β -type hexose glycosidic linkages; when R1 is an alkyl group of 6-8 carbons and R2 is a diolefin of 14 carbons, it has very desirable specificity for enzymes that hydrolyze alpha-type hexose glycosidic linkages. In addition, when R1 is an alkyl group of 6 carbons, it has more excellent specificity to an enzyme having a function of hydrolyzing glucoside, and when R1 is an alkyl group of 8 carbons, it has more excellent specificity to an enzyme having a function of hydrolyzing galactoside. Thus, when more than one lysosomal storage disease is detected simultaneously, different substrates designed by the invention can be adopted for respective enzymes, the detection results are not affected mutually, and the specificity and sensitivity of the detection results can be ensured.
Among the above-mentioned compounds for detecting enzymes associated with Lysosomal Storage Diseases (LSDs), G is D-glucose or D-galactose as a preferred embodiment.
Among the above-mentioned compounds for detecting enzymes associated with Lysosomal Storage Diseases (LSDs), as a preferred embodiment, R1 is C5-C8An alkyl group.
Among the above-mentioned compounds for detecting enzymes associated with Lysosomal Storage Diseases (LSDs), as a preferred embodiment, R2 is C12-C20Alkyl or C12-C20An alkenyl group.
In the above compounds for detecting enzymes associated with Lysosomal Storage Diseases (LSDs), as a preferred embodiment, R3 and R4 are both CH3R3 and R4 on the benzene ring are both CH3Has more excellent contact flexibility of the substrate and the related enzyme compared with the condition that the two are both hydrogen.
Among the above compounds for detecting enzymes associated with Lysosomal Storage Diseases (LSDs), as a preferred embodiment, the compounds have the following structures represented by formula ii or iii:
Preferably, G in formula II is β -glucose and G in formula III is β -galactose.
Among the above compounds for detecting an enzyme associated with a lysosomal storage disease, as a preferred embodiment, the compound has a structure represented by formula IV or formula V below:
Preferably, G in formula IV is alpha-glucose and G in formula V is alpha-galactose.
Among the above-mentioned compounds for detecting Lysosomal Storage Disease (LSDs) -associated enzymes, as a preferred embodiment, the LSDs-associated enzymes include one or more of acid β -glucocerebrosidase (ABG), β -galactocerebroside esterase (GALC), acid α -Galactosidase (GLA) and acid α -Glucosidase (GAA). The compounds of the invention can be used as targeting substrates for specific lysosomal enzymes, the substrates for these enzymes being used to detect the activity of the corresponding enzymes in a sample, whereby they can be used to detect the following lysosomal storage diseases: mucopolysaccharidosis type i (MPS-i), Fabry disease (Fabry), Gaucher disease (Gaucher), Krabbe disease (Krabbe), Niemann pick disease (a/B) and Pompe disease (Pompe).
An internal standard compound corresponding to the above-described compounds for detecting enzymes associated with Lysosomal Storage Diseases (LSDs) having the structure shown in formula vi below:
wherein R1 is C1-C10Alkyl or C2-C20An alkenyl group;
r2 is C1-C20Alkyl, C having a substituent of N, O or S1-C20Alkyl radical, C3-C20Alkenyl or C having a substituent of N, O or S3-C20An alkenyl group;
r3 and R4 are each independently C1-C3Alkyl or H;
and in the compound of the formula VI, an isotope D,13C、15N、17O、18O、34One or more of S;
the internal standard of the invention is used to measure the amount of product formed by the action of the enzyme on the substrate of the invention. The internal standard is structurally identical to the product produced by the enzyme upon action on the substrate, but some elements are replaced by their isotopes. Preferably, the different substrates correspond to different internal standards, and when formula II is used as a substrate the R1 and R2 moieties in the corresponding internal standards should be the same as the R1 and R2 moieties of formula II, and similarly, when formula III, formula IV and formula VI are used as substrates for enzymes, the R1 and R2 moieties in their respective corresponding internal standards should be the same as the R1 and R2 moieties on the corresponding substrates. Thus, the internal standards of the invention are analogs of stable isotopically labeled cleavage products in which one or more atoms are replaced by an isotope of the corresponding atom to produce a change in mass, e.g., H on the alkyl group is replaced by D, and a "heavier" internal standard molecule having a substituted D exhibits a different m/z from the cleavage product on mass spectrometry spectra results, the change in mass being used to identify the cleavage product from the internal standard in mass spectrometry experiments, the internal standard being added to an assay solution and detected simultaneously with the enzyme acting on the substrate.
Preferably, the oxygen of the amide bond to R1 is18O, nitrogen are15N and hydrogen are D.
A kit for detecting Lysosomal Storage Disease (LSDs) -associated enzymes, comprising:
the above compounds for detecting Lysosomal Storage Disease (LSDs) -associated enzymes and the corresponding internal standard compounds.
The substrate of the invention can be used for detecting the activity of enzymes related to the lysosomal storage disease by the tandem mass spectrometry and the multiple immunoassay method, but is particularly suitable for detecting the activity of LSDs related enzymes by the tandem mass spectrometry.
The sample used in the detection using tandem mass spectrometry may be a dry filter paper sample in which serum, plasma, whole blood, urine, saliva, or the like is deposited on a filter paper and dried. The detection method specifically comprises the following steps: a 3mm diameter sample of DBS was taken with a punch and deposited in a deep or microtiter plate well to which the assay solution was added. The assay solution includes buffers (e.g., Tris-HCl buffer), substrate and internal standards, and optionally protease inhibitors such as inhibitors for competitive glycosidases, resulting in a sample mixture. The sample mixture was then incubated at 30-41 ℃ for 2-5 h. After incubation, the enzymatic reaction is stopped by adding a solution for precipitating the enzyme (such as alcohol, acetonitrile or diluted trifluoroacetic acid). A portion of the incubated product is transferred to a new tube and a new volume of methanol, acetonitrile, water-methanol mixture or water-acetonitrile mixture, etc., equal to the volume of incubated product in the tube is added to be compatible with tandem mass spectrometry analysis. This method of operation can reduce the amount of endogenous competitor species in order to relatively increase the sensitivity of tandem mass spectrometry analysis. The diluted sample was injected directly into the tandem mass spectrometer. The tandem mass spectrometer was set to simultaneously detect the added substrate, enzyme product and corresponding internal standard. Such detection is achieved by a parent ion scan, or a multiple reaction monitoring scan. Relative abundance of observed product and corresponding internal standard to measure the corresponding enzyme activity.
Thus, reagents required for tandem mass spectrometry detection as described above, such as protease inhibitors, alcohols, acetonitrile, and the like, can also be included in the kits of the invention.
Compared with the prior art, the invention has the following remarkable effects: the lysosomal storage disease-associated enzyme comprises one or more of acid β -glucocerebrosidase, β -galactocerebroside, α -galactosidase, and acid α -glucosidase. The compound for detecting the enzyme related to the lysosomal storage disease, provided by the invention, has the structure that the part for connecting the glucoside and the ammonia alcohol contains the benzene ring and the benzene ring is connected with the end part of the ammonia alcohol through an ester bond, so that the structure enhances the binding specificity of the substrate and the related enzyme and can improve the reaction efficiency of the enzyme and the substrate. In addition, the preferred formulas of R1 and R2 cooperate to increase the specificity of detection and increase the detection sensitivity, thereby improving the stability, specificity and reactivity of the substrate and improving the efficiency, reproducibility and accuracy of the assay.
Drawings
FIG. 1 shows the results of liquid chromatography and mass spectrometry of Compound A.
FIG. 2 shows the results of liquid chromatography and mass spectrometry of Compound B.
FIG. 3 shows the results of liquid chromatography and mass spectrometry of Compound C.
Detailed Description
The following description of specific embodiments is merely exemplary in nature and is in no way intended to limit the scope of the invention, its application, or uses, which may, of course, vary. The definitions and terms used herein are not to be construed as limitations on the scope or practice of the invention, but are presented for illustrative and descriptive purposes only.
Unless defined otherwise, terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. It will be further understood that terms are to be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and the present invention, and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.
EXAMPLE 1 preparation of Compound A for detecting enzymes associated with lysosomal storage diseases
The structural formula of compound a is as follows:
the preparation method comprises the following steps:
(1) adding 195g of 4-hydroxy-3, 5-dimethyl methyl benzoate into a reaction system with a stirring device, a thermometer and a water diversion device, heating to 80 ℃, slowly adding 200g of beta-D-glucose in the stirring process, adding macroporous strong-acid cation exchange resin D00143 g when stirring until the solution is a colorless transparent homogeneous solution, controlling the reaction temperature to be 100 ℃, controlling the absolute pressure of the reaction to be 60mmHg, and stirring at the speed of 100r/min for reaction, and simultaneously evaporating water generated by the reaction; when the content of residual sugar is lower than 0.2%, the reaction is finished, the reaction liquid is subjected to reduced pressure filtration, and the macroporous strong-acid cation exchange resin D001 catalyst is recovered; then extracting with ethyl acetate for three times, combining ethyl acetate phases, evaporating to dryness, and separating by column chromatography (petroleum ether: ethyl acetate: 3:1) to obtain a total of 152g of product 1. The specific reaction equation is as follows:
(2) dissolving the product 1 with methanol, reacting at room temperature for 2h in the presence of potassium hydroxide solution, removing methanol by spinning, adjusting the pH of the remaining reaction solution to 5.5, and washing with water to obtain a product 2, wherein the specific reaction is as follows:
(3) adding 100mL of acetonitrile, 50g of product 2 and 68g of N-hexanoyl-D-sphingosine into an esterification reaction device, adding 15g of DMAP as a catalyst, wherein the reaction temperature is about 120 ℃, the reaction pressure of a reactor is 0.10MPaG, and the reaction time is 5 h. After the reaction, a white solid compound A was obtained by distillation, and 62g in total was obtained. The specific reaction is as follows:
compound a, analyzed by high performance liquid HPLC, had a molecular weight: 723.
the purity of the compound A is 99.342% by liquid mass analysis, see figure 1.
EXAMPLE 2 preparation of Compound B for detection of enzymes associated with lysosomal storage diseases
The structural formula of compound B is as follows:
compound B was prepared in substantially the same manner as Compound A, except that in step (1), β -D-glucose was replaced with β -D-galactose, and in step (3), N-hexanoyl-D-sphingosine was replaced with N-octanoyl-D-sphingosine, and the preparation process was the same as in example 1.
The compound B obtained was analyzed by high performance liquid HPLC and had a molecular weight of: 751.
the purity of the compound B is 98.985% by liquid mass analysis, and the result is shown in figure 2.
EXAMPLE 3 preparation of Compound C for detection of enzymes associated with lysosomal storage diseases
The structural formula of compound C is as follows:
compound C was prepared in substantially the same manner as Compound A, except that in step (1), β -D-glucose was replaced with α -D-galactose, and in step (3), N-hexanoyl-D-sphingosine was replaced with N-octanoyl-D-sphingosine-10, and the preparation process was the same as in example 1.
The compound C obtained was analyzed by high performance liquid HPLC and had a molecular weight of: 761.
the purity of the compound C is 99.92% by liquid chromatography, and the result is shown in figure 3.
EXAMPLE 4 preparation of Compound D for detection of enzymes associated with lysosomal storage diseases
The structural formula of compound D is as follows:
compound D was prepared in substantially the same manner as Compound A, except that in step (1), β -D-glucose was replaced with α -D-glucose, and in step (3), N-hexanoyl-D-ceramide was replaced with N-hexanoyl-D-sphingosine-10, and the preparation process was the same as in example 1.
The compound C obtained was analyzed by high performance liquid HPLC and had a molecular weight of: 733.
EXAMPLE 5 preparation of Compound E for detection of enzymes associated with lysosomal storage diseases
The structural formula of compound E is as follows:
compound E was prepared essentially in the same manner as Compound A, except that in step (1), β -D-glucose was replaced with α -D-galactose, and in step (3), N-hexanoyl-D-sphingosine was replaced with N-octanoyl-D-sphingosine, and the preparation process was the same as in example 1.
The compound C obtained was analyzed by high performance liquid HPLC and had a molecular weight of: 751.
EXAMPLE 6 preparation of Compound F for detection of enzymes associated with lysosomal storage diseases
The structural formula of compound F is as follows:
compound F was prepared in substantially the same manner as Compound A, except that in step (1), β -D-glucose was replaced with β -D-galactose, and in step (3), N-hexanoyl-D-sphingosine was replaced with N-octanoyl-D-sphingosine-10, and the preparation process was the same as in example 1.
The compound C obtained was analyzed by high performance liquid HPLC and had a molecular weight of: 761.
EXAMPLE 7 preparation of Compound G for detecting an enzyme associated with lysosomal storage disease
The structural formula of compound G is as follows:
compound G was prepared in substantially the same manner as Compound A, except that in step (1), β -D-glucose was replaced with β -D-glucose, and in step (3), N-hexanoyl-D-ceramide was replaced with N-hexanoyl-D-sphingosine-10, and the preparation process was the same as in example 1.
The compound C obtained was analyzed by high performance liquid HPLC and had a molecular weight of: 733.
EXAMPLE 8 preparation of Compound H for detection of enzymes associated with lysosomal storage diseases
The structural formula of compound H is as follows:
compound H was prepared in substantially the same manner as Compound A, except that in step (1), β -D-glucose was replaced with α -D-glucose, and the preparation process was otherwise the same as in example 1.
The compound C obtained was analyzed by high performance liquid HPLC and had a molecular weight of: 723.
EXAMPLE 9 preparation of internal Standard Compound 1
The same internal standard was prepared for examples 1 and 8, since the enzyme products of both were identical, and therefore the same internal standard can be used, with the specific structure as follows:
the preparation method comprises the following steps: adding 100mL of acetonitrile, 25g of 4-hydroxy-3, 5-dimethylbenzoic acid and 69g of N-hexanoyl-D-sphingosine into an esterification reaction device, adding 10g of DMAP as a catalyst, reacting at about 110 ℃, at the reaction pressure of 0.20MPaG for 3 h. After the reaction was completed, the internal standard 1 was obtained by distillation to give a total of 43 g.
The internal standard 1 obtained was analyzed by high performance liquid HPLC and had a molecular weight of: 548.
EXAMPLE 10 preparation of internal Standard Compound 2
The same internal standard was prepared for examples 2 and 5, since the enzyme products of both were identical, and therefore the same internal standard could be used, with the specific structure as follows:
the preparation method comprises the following steps:
adding 100mL of acetonitrile, 25g of 4-hydroxy-3, 5-dimethylbenzoic acid and 70g of N-octanoyl-D-sphingosine into an esterification reaction device, adding 10g of DMAP as a catalyst, reacting at about 110 ℃, at the reaction pressure of 0.20MPaG for 3 h. After the reaction was completed, the internal standard 2 was obtained by distillation, and a total amount of 45g was obtained.
The internal standard 2 obtained was analyzed by high performance liquid HPLC and had a molecular weight of: 576.
EXAMPLE 11 preparation of internal Standard Compound 3
The same internal standard was prepared for examples 3 and 6, since the enzyme products of both were identical, and therefore the same internal standard could be used, with the specific structure as follows:
internal standard 3, wherein the oxygen of the amide bond to which R1 is attached is18O, nitrogen are15N, hydrogen is D;
the preparation method comprises the following steps:
adding 100mL of acetonitrile, 25g of 4-hydroxy-3, 5-dimethylbenzoic acid and 70g of N-octanoyl-D-sphingosine gelophin-10 into an esterification reaction device, adding 10g of DMAP as a catalyst, reacting at the temperature of about 110 ℃, the reaction pressure of a reactor is 0.20MPaG, and the reaction time is 3 hours. After the reaction was completed, the internal standard 3 was obtained by distillation to give a total of 40 g.
The internal standard 3 obtained was analyzed by high performance liquid HPLC and had a molecular weight of: 586.
EXAMPLE 12 preparation of internal Standard Compound 4
The same internal standards were prepared for examples 4 and 7, since the cleavage products were identical, and the same internal standards were used, and the specific structures are as follows:
the preparation method comprises the following steps:
adding 100mL of acetonitrile, 24g of 4-hydroxy-3, 5-dimethylbenzoic acid and 68g of N-hexanoyl-D-sphingosine gelophin-10 into an esterification reaction device, adding 10g of DMAP as a catalyst, reacting at the temperature of about 110 ℃, the reaction pressure of a reactor is 0.20MPaG, and the reaction time is 3 h. After the reaction was completed, the internal standard 4 was obtained by distillation to give a total of 42 g.
The internal standard 4 obtained was analyzed by high performance liquid HPLC and had a molecular weight of: 558.
test example 1 Simultaneous detection of lysosomal multiple enzyme activities in a sample by tandem Mass Spectrometry
(1) Preparing dried blood tablets: smearing the blood of a subject on filter paper, and drying to obtain a dry blood slice sample;
(2) and (3) processing of a sample: taking 3mm dry blood filter paper sheet by puncher, placing in 96-well plate, adding 80 μ L extractive solution (20mmol/L NaH) per well2PO4) And sealing and shaking for extraction at 37 ℃ for 1h to obtain a blood spot extracting solution.
(3) Preparation of substrate and corresponding internal standard mixed solution: the substrate compounds A to D prepared in examples were added to 0.45ml of a 120g/L sodium taurocholate solution, mixed well and added to 14.67. mu.l of a blood spot extract
Each of the substrate compounds A to D prepared in examples 1, 2, 3 and 4 had a final concentration of 100. mu. mol/L, while adding internal standards 1 to 4 to give a final concentration of 1. mu. mol/L, and further adding thereto a sodium acetate buffer solution containing sodium taurocholate to give a final concentration of 0.5mol/L of sodium acetate, the final volume of the mixture being 30. mu.l.
(4) The mixture was then incubated at 37 ℃ for 20h with rotary shaking (150rpm), 50: 50(V/V) methanol/ethyl acetate was added to the mixture to stop the enzymatic reaction after incubation, followed by 300 μ l HPLC grade ethyl acetate and 300 μ l water, and after centrifugation the upper layer liquid was transferred to a new 96 well plate and evaporated under nitrogen. This was then reconstituted with 80% acetonitrile in water containing 0.1% formic acid for on-machine testing.
(5) The substrate, enzyme reaction product and internal standard were detected by MS/MS analysis. The mobile phase is 80 vol% acetonitrile water solution containing 0.1 vol% formic acid, the flow rate is 0.2ml/min, the measuring time of each sample is 2min, and the sample amount is 10 mul. For mass spectrometry, the electrospray source is operated in positive ion mode and ions are detected in parent ion scan mode. And carrying out quantitative analysis according to the peak intensity ratio (P/IS) of the enzyme reaction product and the internal standard ion to obtain the enzyme activity.
As a result: the activities of four enzymes GLA, ABG, GALC and GAA are as follows: 12.12. mu. mol/(Lh), 14.83. mu. mol/(Lh), 8.04. mu. mol/(Lh), 10.77. mu. mol/(Lh).
Test example 2 Simultaneous detection of lysosomal multiple enzyme activities in samples Using tandem Mass Spectrometry
The test procedures in this test example were the same as in test example 1 except that the substrates of examples 1 to 4 in test example 1 were replaced with the substrate compounds of examples 5 to 8, and the dried blood sample was derived from the same source, i.e., from the same test subjects.
As a result: the activities of four enzymes GLA, ABG, GALC and GAA are as follows: 9.32. mu. mol/(Lh), 10.59. mu. mol/(Lh), 6.18. mu. mol/(Lh), 8.29. mu. mol/(Lh).
Test example 3 Simultaneous detection of acidic β -glucocerebrosidase (ABG) Activity in samples Using tandem Mass Spectrometry
The substrate compound employed in this test example has the following structure:
the corresponding internal standard structure is:
the detection method comprises the following steps: the test procedures of this example were the same as in example 1 except that the substrates and internal standards of examples 1 to 4 in example 1 were replaced with the substrate compounds and internal standards of the present example, and the dried blood sample was derived from the same test subjects from the same sources.
As a result: the ABG enzyme activity was: 8.24. mu. mol/(L.h).
As is clear from test examples 1 to 3, detection of various enzymatic activities of lysosomes by using the substrate compound of the present invention has higher substrate stability, specificity and reactivity, and the enzymatic activity measured by using the substrate compound used in test example 1 is 1.3 to 1.4 times that of test example 2 and 1.8 times that of test example 3.
Claims (5)
1. A compound for detecting an enzyme associated with a lysosomal storage disease, having the structure shown below:
Wherein G in the formula I is beta-glucose, G in the formula II is beta-galactose, G in the formula III is alpha-glucose, and G in the formula IV is alpha-galactose.
2. The compound for detecting an enzyme associated with a lysosomal storage disease according to claim 1, wherein the enzyme associated with a lysosomal storage disease is selected from one or more of acid β -glucocerebrosidase, β -galactocerebrosidase, α -galactosidase, and acid α -glucosidase.
3. An internal standard compound corresponding to the compound for detecting an enzyme associated with a lysosomal storage disease according to any one of claims 1-2, having the structure shown below:
4. A kit for detecting an enzyme associated with a lysosomal storage disease, comprising:
the compound for detecting an enzyme associated with a lysosomal storage disease according to any one of claims 1-2 and the corresponding internal standard compound according to claim 3.
5. The kit of claim 4, further comprising reagents required for tandem mass spectrometry detection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010232077.7A CN111269280B (en) | 2020-03-27 | 2020-03-27 | Compound, corresponding internal standard and kit for detecting enzyme related to lysosomal storage disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010232077.7A CN111269280B (en) | 2020-03-27 | 2020-03-27 | Compound, corresponding internal standard and kit for detecting enzyme related to lysosomal storage disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111269280A CN111269280A (en) | 2020-06-12 |
| CN111269280B true CN111269280B (en) | 2021-07-13 |
Family
ID=71002730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010232077.7A Active CN111269280B (en) | 2020-03-27 | 2020-03-27 | Compound, corresponding internal standard and kit for detecting enzyme related to lysosomal storage disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111269280B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102014929A (en) * | 2008-03-13 | 2011-04-13 | 珀金埃尔默健康科学有限公司 | Enzymatic substrates for multiple detection systems |
| CN102943106A (en) * | 2006-03-13 | 2013-02-27 | 珀金埃尔默健康科学股份有限公司 | Substrates and internal standards for mass spectroscopy detection |
| CN105247068A (en) * | 2013-03-15 | 2016-01-13 | 珀金埃尔默健康科学股份有限公司 | Compounds and methods relating to testing for lysosomal storage disorders |
| CN105636606A (en) * | 2013-09-05 | 2016-06-01 | 华盛顿大学商业中心 | Reagents and methods for screening mps i, ii, iiia, iiib, iva, vi, and vii |
| CN107109462A (en) * | 2014-09-02 | 2017-08-29 | 珀金埃尔默健康科学股份有限公司 | It is related to the disorderly method of test Lysosomal storage |
-
2020
- 2020-03-27 CN CN202010232077.7A patent/CN111269280B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102943106A (en) * | 2006-03-13 | 2013-02-27 | 珀金埃尔默健康科学股份有限公司 | Substrates and internal standards for mass spectroscopy detection |
| CN102014929A (en) * | 2008-03-13 | 2011-04-13 | 珀金埃尔默健康科学有限公司 | Enzymatic substrates for multiple detection systems |
| CN105247068A (en) * | 2013-03-15 | 2016-01-13 | 珀金埃尔默健康科学股份有限公司 | Compounds and methods relating to testing for lysosomal storage disorders |
| CN105636606A (en) * | 2013-09-05 | 2016-06-01 | 华盛顿大学商业中心 | Reagents and methods for screening mps i, ii, iiia, iiib, iva, vi, and vii |
| CN107109462A (en) * | 2014-09-02 | 2017-08-29 | 珀金埃尔默健康科学股份有限公司 | It is related to the disorderly method of test Lysosomal storage |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111269280A (en) | 2020-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0270946B1 (en) | Chromogenic acridinone enzyme substrates | |
| US8476414B2 (en) | Substrates and internal standards for mass spectrometry detection | |
| Crook | The determination of plasma or serum sialic acid | |
| EP3041499B1 (en) | Reagents and methods for screening mps i, ii, iiia, iiib, iva, vi, and vii | |
| Hehre et al. | Scope and mechanism of carbohydrase action. Stereospecific hydration of 2, 6-anhydro-1-deoxy-D-gluco-hept-1-enitol catalyzed by. alpha.-and. beta.-glucosidases and an inverting exo-. alpha.-glucanase | |
| US20220010354A1 (en) | Compounds and methods relating to lysosomal storage disorders | |
| WO2001094941A2 (en) | Diagnostic methods for pompe disease and other glycogen storage diseases | |
| US20090253117A1 (en) | Enzymatic substrates for multiple detection systems | |
| CN111269280B (en) | Compound, corresponding internal standard and kit for detecting enzyme related to lysosomal storage disease | |
| Qian-Cutrone et al. | Glucolipsin A and B, two new glucokinase activators produced by Streptomyces purpurogeniscleroticus and Nocardia vaccinii | |
| EP3196274B1 (en) | Sulfonated coumarins, synthesis thereof | |
| Satomura et al. | Synthesis of p-nitrophenyl 65-O-benzyl-α-maltopentaoside, a substrate for alpha amylases | |
| EP2700717A1 (en) | Method for the diagnosis of lysosomal storage diseases | |
| EP0402699B1 (en) | Chromogenic dibenzoxazepinone and dibenzothiazepinone enzyme substrates | |
| EP0459536A1 (en) | Chromogenic acridinone enzyme substrates | |
| Tokutake et al. | Syntheses of subtractively modified 2-chloro-4-nitrophenyl β-maltopentaosides and their application to the differential assay of human alpha-amylases | |
| US6534637B2 (en) | Synthesis of chlorophenol red glucuronic acid | |
| US7537909B2 (en) | Enzymatic method of producing 4-O-β-D-galactopyranosyl-D-xylose, 4-O-β-D-galactopyranosyl-D-xylose obtained using said method, compositions contain same and the use thereof in evaluating intestinal lactase | |
| US5183743A (en) | Chromogenic dibenzoxazepinone and dibenzothiazepinone enzyme substrates | |
| JPS6323199B2 (en) | ||
| Barranger et al. | Newborn Screening for Lysosomal Storage Disorders | |
| JP2000346849A (en) | Detection means for new disease | |
| JPH0246299A (en) | Determination of glycolipid in serum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhai Yanhong Inventor after: Sun Nian Inventor after: Wang Lihui Inventor after: Shi Haowei Inventor after: Gao Ya Inventor after: Ding Liang Inventor after: Wang Xiao Inventor after: Li Lin Inventor after: Cao Zheng Inventor after: Ma Zhijun Inventor after: Lu Kaizhi Inventor after: Cai Bolun Inventor after: Niu Yanyan Inventor after: Xiao Bingxin Inventor after: Pan Yuanyuan Inventor before: Li Lin Inventor before: Sun Nian Inventor before: Wang Lihui Inventor before: Shi Haowei Inventor before: Gao Ya Inventor before: Ding Liang Inventor before: Wang Xiao Inventor before: Zhai Yanhong Inventor before: Cao Zheng Inventor before: Ma Zhijun Inventor before: Lu Kaizhi Inventor before: Cai Bolun Inventor before: Niu Yanyan Inventor before: Xiao Bingxin Inventor before: Pan Yuanyuan |